gvtcx

NHS National Framework for Aripiprazole prolonged release injection

NHS England Published 27 May 2026 Find a Tender
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£32,140,000 (£38,568,000 inc. VAT)
Statuscomplete
RegionNorth East, North West, East Midlands, West Midlands, East of England, South East, South West
Procedureopen
OCIDocds-h6vhtk-0668bf

Awards (3)

This procurement was awarded to 3 suppliers. Values shown are per-award; the notice total is £32,140,000.

SupplierValueDateStatus
Otsuka Pharmaceuticals UK Limited shared £32,140,000 28 Jul 2026 active
Perennial Pharma Ltd shared £32,140,000 28 Jul 2026 active
Sun Pharma UK Ltd shared £32,140,000 28 Jul 2026 active

description

Project title: NHS National Framework for Aripiprazole prolonged release injection commencing 1st February 2027

Offer reference number: CM/TNS/26/5741

Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months.

CM/TNS/26/5741 Aripiprazole prolonged release injection

Lot 1 CESW 01/02/2027 to 30/09/2027 (8 months)

Lot 2 NWLN 01/02/2027 to 31/01/2029 (24 months)

Lot 3 LSNE 01/02/2027 to 31/05/2028 (16 months)

Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

notice history

3 notices published against this procurement.

PublishedTypeRegimeNotice
12 Mar 2026 Pipeline notice (UK1) Procurement Act 2023 022493-2026
2 Apr 2026 Preliminary market engagement (UK2) Procurement Act 2023 030759-2026
27 May 2026 Tender notice (UK4) Procurement Act 2023 049710-2026

more from NHS England

all contracts from this buyer →

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.